H. Charles Manning, Ph.D.
Department of Cancer Systems Imaging, Division of Diagnostic Imaging
Present Title & Affiliation
Primary Appointment
Professor, Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Scientific Director, Department of Center for Advanced Biomedical Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
Graduate Faculty, Division of Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, TX
Research Interests
Research objective: Development, validation, implementation, and clinical translation of imaging and chemical probes to non-invasively quantify molecular events in vivo.
Representative research key words: Precision imaging diagnostics; precision medicine; drug development; cellular metabolism; glutamine; molecular imaging biomarkers; oncology; neuroscience; cell signaling; proliferation; cell death; translocator protein; drug development; medicinal chemistry; high-throughout, small-molecule screening; treatment response; positron emission tomography (PET); single photon emission computed tomography (SPECT); radiochemistry; radiopharmaceuticals; theranostics; magnetic resonance imaging (MRI), cyclotron.
Education & Training
Degree-Granting Education
| 2004 | Texas Tech University, Lubbock, TX, USA, PHD, Chemistry |
| 2000 | Tarleton State University, Stephenville, TX, USA, BS, Chemistry |
Postgraduate Training
| 2004-2006 | Research Fellowship, Vanderbilt University, Department of Radiology and Radiological Sciences, Nashville, TN |
Experience & Service
Academic Appointments
Vanderbilt Ingram Professor of Cancer Research, Division of Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TX, 2015 - 2020
Professor, Vanderbilt University - Chemistry, Nashville, TN, 2015 - 2020
Professor, Vanderbilt University - Biomedical Engineering, Nashville, TN, 2015 - 2020
Professor, Department of Neurosurgery, Vanderbilt University - Neurosurgery, Nashville, TN, 2015 - 2020
Professor of Radiology and Radiological Sciences with Tenure, Vanderbilt University, Nashville, TN, 2015 - 2020
Associate Professor of Radiology and Radiological Sciences with Tenure, Vanderbilt University, Nashville, TN, 2012 - 2015
Associate Professor, Vanderbilt University, Nashville, TN, 2012 - 2015
Assistant Professor of Radiology and Radiological Sciences with Tenure, Vanderbilt University, Nashville, TN, 2008 - 2012
Assistant Professor, Vanderbilt University, Nashville, TN, 2007 - 2012
Assistant Professor, Department of Neurosurgery, Vanderbilt University, Nashville, TN, 2006 - 2012
Research Assistant Professor, Vanderbilt University, Nashville, TN, 2006 - 2008
Other Appointments/Responsibilities
Member, Institutional Committee, The University of Texas MD Anderson Cancer Center - Cancer Neuroscience Program (CNP) leadership CNP Unit Steering Committee Introduction, Houston, TX, 2024 - Present
External Advisory Committee Member, University of Texas RGV - Integrated Cancer Research Core (ICRC), Houston, TX, 2021 - Present
Program in Chemical and Physical Biology, Vanderbilt University, Nashville, TN, 2008 - 2020
Post-doctoral Research Fellow, Vanderbilt University, Institute of Imaging Science and Department of Radiology, Nashville, TN, 2004 - 2006
Graduate Student and Research Associate, Texas Tech University, Department of Chemistry and Biochemistry, Lubbock, TX, 2000 - 2004
Undergraduate Research Assistant, Tarleton State University, Department of Physical and Environmental Sciences, Stephenville, TX, 1996 - 2000
Institutional Committee Activities
Member, DI Research Infrastructure Committee, 2022 - Present
Co-Chair, DI Research Infrastructure Education Subcommittee, 2022 - Present
Member, CSI Chemistry/Radiochemistry Committee, 2022 - Present
Member, The University of Texas MD Anderson Cancer Center Institutional Radiation Safety Committee, 2022 - Present
Associate Member, Steering Committee, Graduate Program in Medical Physics, 2022 - Present
Member, SAIF Steering Committee, 2021 - Present
Member, CABI Executive Steering Committee, 2021 - Present
Member, DI DEI - Diversity, Equity and Inclusion Committee, 2021 - 2023
Member, Image-Guided Cancer Therapy (IGCT) Research Program, 2021 - Present
Member, DI - Research Functional Committee (DI-RFC), 2020 - Present
Member, DI - Imaging Physics Dept - Radiological Physics Section Chief - Search Committee, 2020 - Present
Member, DI - Innovations Task Force, 2020 - Present
Member, DI - CABI Future Operations Sub-Committee, 2020 - Present
Member, DI - Clinical Operations Committee, 2020 - Present
Committee Chair, The Department of Cancer Systems Imaging Faculty Search Committee, 2020 - Present
Honors & Awards
| 2020 | UT Rising Star, The University of Texas System |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Pantel AR, Bae SW, Li EJ, O'Brien SR, Manning HC. PET Imaging of Metabolism, Perfusion, and Hypoxia: FDG and Beyond. Cancer J 30(3):159-169, 2024. PMID: 38753750.
- Coll RP, Bright SJ, Martinus DKJ, Georgiou DK, Sawakuchi GO, Manning HC. Alpha Particle-Emitting Radiopharmaceuticals as Cancer Therapy: Biological Basis, Current Status, and Future Outlook for Therapeutics Discovery. Mol Imaging Biol. e-Pub 2023. PMID: 37845582.
- Lin M, Ta RT, Manning HC. Simplified and highly-reliable automated production of [18F]FSPG for clinical studies. EJNMMI Radiopharm Chem 8(1):15, 2023. e-Pub 2023. PMID: 37486582.
- Moore SM, Quirk JD, Lassiter AW, Laforest R, Ayers GD, Badea CT, Fedorov AY, Kinahan PE, Holbrook M, Larson PEZ, Sriram R, Chenevert TL, Malyarenko D, Kurhanewicz J, Houghton AM, Ross BD, Pickup S, Gee JC, Zhou R, Gammon ST, |Manning HC||, Roudi R, Dalrup-Link HE, Lewis MT, Rubin DL, Yaneelov TE, Shoghi KI. Co-Clinical Imaging Metadata Information (CIMI) for Cancer Research to Promote Open Science, Standardization, and Reproducibility in Preclinical Imaging. Tomography 9(3):995-1009, 2023.
- Malyarenko D, Amouzandeh G, Pickup S, Zhou R, Manning HC, Gammon ST, Shoghi KI, Quirk JD, Sriram R, Larson P, Lewis MT, Pautler RG, Kinahan PE, Muzi M, Chenevert TL. Evaluation of Apparent Diffusion Coefficient Repeatability and Reproducibility for Preclinical MRIs Using Standardized Procedures and a Diffusion-Weighted Imaging Phantom. Tomography 9(1):375-386, 2023. e-Pub 2023. PMID: 36828382.
- Bae SW, Wang J, Georgiou DK, Wen X, Cohen AS, Geng L, Tantawy MN, Manning HC. Feasibility of [18F]FSPG PET for Early Response Assessment to Combined Blockade of EGFR and Glutamine Metabolism in Wild-Type KRAS Colorectal Cancer. Tomography 9(2):497-508, 2023. e-Pub 2023. PMID: 36961000.
- Peehl, DM, Badea CT, Chenevert TL, Daldrup-Link HE, Ding L, Dobrolecki LE, Houghton AM, Kinahan PE, Kurhanewicz J, Lewis MT, Li S, Luker GD, Ma CX, Manning HC, Mowery YM, O'Dwyer PJ, Pautler RG, Rosen MA, Roudi R, Ross BD, Shoghi KI, Sriram R, Talpaz M, Wahl, RL, Zhou R. Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials. Tomography(9):657-680, 2023.
- Lin M, Coll RP, Cohen AS, Georgiou DK, Manning HC. PET Oncological Radiopharmaceuticals: Current Status and Perspectives. Molecules 27(20):6790, 2022. PMID: 36296381.
- Wardak M, Sonni I, Fan AP, Minamimoto R, Jamali M, Hatami N, Zaharchuk G, Fischbein N, Nagpal S, Li G, Koglin N, Berndt M, Bullich S, Stephens AW, Dinkelborg LM, Abel T, Manning HC, Rosenberg J, Chin FT, Sam Gambhir S, Mittra ES. 18F-FSPG PET/CT Imaging of System xC- Transporter Activity in Patients with Primary and Metastatic Brain Tumors. Radiology 303(3):620-631, 2022. e-Pub 2022. PMID: 35191738.
- Paez R, Shah C, Cords AJ, Muterspaugh A, Helton JE, Antic S, Eisenberg R, Chen H, Grogan E, Manning HC, Walker RC, Mission PP. 18F-FSPG PET imaging for the evaluation of indeterminate pulmonary nodules. PLOS ONE 17(3):e0265427, 2022. e-Pub 2022. PMID: 35294486.
- Jaggupilli A, Ly S, Nguyen K, Anand V, Yuan B, El-Dana F, Yan Y, Arvanitis Z, Piyarathna DWB, Putluri N, Piwnica-Worms H, Manning HC, Andreeff M, Battula VL. Metabolic stress induces GD2+ cancer stem cell-like phenotype in triple-negative breast cancer. British Journal of Cancer 126(4):615-627, 2021. PMID: 34811508.
- Zhang X, Liu F, Payne AC, Nickels ML, Bellan LM, Manning HC. Correction to: High-Yielding Radiosynthesis of [68 Ga]Ga-PSMA-11 Using a Low-Cost Microfluidic Device. Mol Imaging Biol 23(6):979. e-Pub 2021. PMID: 34338960.
- Reinfeld BI, Madden MZ, Wolf MM, Chytil A, Bader JE, Patterson AR, Sugiura A, Cohen AS, Ali A, Do BT, Muir A, Lewis CA, Hongo RA, Young KL, Brown RE, Todd VM, Huffstater T, Abraham A, O'Neil RT, Wilson MH, Xin F, Tantawy MN, Merryman WD, Johnson RW, Williams CS, Mason EF, Mason FM, Beckermann KE, Vander Heiden MG, Manning HC, Rathmell JC, Rathmell WK. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature 593(7858):282-288, 2021. e-Pub 2021. PMID: 33828302.
- Cohen AS, Grudzinski J, Smith GT, Peterson TE, Whisenant JG, Hickman TL, Kristen Ciombor KK, Cardin D, Eng C, Goff LW, Das S, Coffey RJ, Berlin JD, Manning HC. First-in-human PET imaging and estimated radiation dosimetry of L-[5-<SUP>11</SUP>C]-glutamine in patients with metastatic colorectal cancer. J Nucl Med 63(1):36-43. e-Pub 2021. PMID: 33931465.
- Edwards DN, Ngwa VM, Raybuck AL, Wang S, Hwang Y, Kim LC, Cho SH, Paik Y, Wang Q, Zhang S, Manning HC, Rathmell JC, Cook RS, Boothby MR, Chen J. Selective glutamine metabolism inhibition in tumor cells improves anti-tumor T lymphocyte activity in triple-negative breast cancer. J Clin Invest 131(4):e140100, 2021. e-Pub 2020. PMID: 33320840.
- Zhang X, Liu F, Payne AC, Nickels ML, Bellan LM, Manning HC. High-Yielding Radiosynthesis of [68Ga]Ga-PSMA-11 Using a Low-Cost Microfluidic Device. Mol Imaging Biol 22(5):1370-1379, 2020. PMID: 32632739.
- Cohen AS, Geng L, Zhao P, Fu A, Schulte ML, Graves-Deal R, Washington MK, Berlin J, Coffey RJ, Manning HC. Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer. Transl Oncol 13(10):100828, 2020. e-Pub 2020. PMID: 32652471.
- Cohen AS, Li J, Hight MR, McKinley ET, Fu A, Payne AC, Liu Y, Zhang D, Xie Q, Bai M, Ayers GD, Tantawy MN, Smith JA, Revetta F, Washington MK, Shi C, Merchant NB, Manning HC. TSPO-targeted PET and Optical Probes for the Detection and Localization of Pre-Malignant and Malignant Pancreatic Lesions. Clin Cancer Res 26(22):5914-5925. e-Pub 2020. PMID: 32933996.
- Shoghi KI, Badea CT, Blocker SJ, Chenevert TL, Laforest R, Lewis MT, Luker GD, Manning HC, Marcus DS, Mowery YM, Pickup S, Richmond A, Ross BD, Vilgelm AE, Yankeelov TE, Zhou R. Co-Clinical Imaging Resource Program (CIRP): Bridging the Translational Divide to Advance Precision Medicine. Tomography 6(3):273-287, 2020. PMID: 32879897.
- Buck, JR, Saleh S, Claus T, Lovly C, Hight MR, Nickels ML, Tantay MN, Manning HC. N-[18F]-Fluoroacetylcrizotinib: A Potentially Potent and Selective PET Tracer for Molecular Imaging of Non–small Cell Lung Cancer. Bio Org Med Chem Let 30(16), 2020. PMID: 32631505.
- Knapp KA, Nickels ML, Manning HC. The Current Role of Microfluidics in Radiofluorination Chemistry. Mol Imaging Biol 22(3):463-475, 2020. PMID: 31485889.
- Uddin MJ, Wilson AJ, Crews BC, Malerba P, Uddin MI, Kingsley PJ, Ghebreselasie K, Daniel CK, Nickels ML, Tantawy MN, Jashim E, Manning HC, Khabele D, Marnett LJ. Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer. ACS Omega 4(5):9251-9261, 2019. e-Pub 2019. PMID: 31172046.
- Tang D, Li J, Nickels ML, Huang G, Cohen AS, Manning HC. Preclinical Evaluation of a Novel TSPO PET Ligand 2-(7-Butyl-2-(4-(2-[18F]Fluoroethoxy)phenyl)-5-Methylpyrazolo[1,5-a]Pyrimidin-3-yl)-N,N-Diethylacetamide (18F-VUIIS1018A) to Image Glioma. Mol Imaging Biol 21(1):113-121, 2019. PMID: 29869061.
- Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA. Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. Clin Cancer Res 25(4):1435, 2019. PMID: 30770494.
- Joseph JD, Darimont B, Zhou W, Arrazate A, Young A, Ingalla E, Walter K, Blake RA, Nonomiya J, Guan Z, Kategaya L, Govek SP, Lai AG, Kahraman M, Brigham D, Sensintaffar J, Lu N, Shao G, Qian J, Grillot K, Moon M, Prudente R, Bischoff E, Lee KJ, Bonnefous C, Douglas KL, Julien JD, Nagasawa JY, Aparicio A, Kaufman J, Haley B, Giltnane JM, Wertz IE, Lackner MR, Nannini MA, Sampath D, Schwarz L, Manning HC, Tantawy MN, Arteaga CL, Heyman RA, Rix PJ, Friedman L, Smith ND, Metcalfe C, Hager JH. Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. Elife 8, 2019. e-Pub 2019. PMID: 30614786.
- Rosenberg AJ, Nickels ML, Schulte ML, Manning HC. Automated radiosynthesis of 5-[11C]l-glutamine, an important tracer for glutamine utilization. Nucl Med Biol 67:10-14, 2018. e-Pub 2018. PMID: 30359787.
- Smith CT, San Juan MD, Dang LC, Katz DT, Perkins SF, Burgess LL, Cowan RL, Manning HC, Nickels ML, Claassen DO, Samanez-Larkin GR, Zald DH. Ventral striatal dopamine transporter availability is associated with lower trait motor impulsivity in healthy adults. Transl Psychiatry 8(1):269, 2018. e-Pub 2018. PMID: 30531858.
- Okunieff P, Casey-Sawicki K, Lockney NA, Hoppe BS, Enderling H, Pinnix C, Welsh J, Krishnan S, Yothers G, Brown M, Knox S, Bristow R, Spellman P, Mitin T, Nabavizadeh N, Jaboin J, Manning HC, Feng F, Galbraith S, Solanki AA, Harkenrider MM, Tuli R, Decker RH, Finkelstein SE, Hsu CC, Ha CS, Jagsi R, Shumway D, Daly M, Wang TJC, Fitzgerald TJ, Laurie F, Marshall DT, Raben D, Constine L, Thomas CR, Kachnic LA. Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017. Clin Cancer Res 24(15):3500-3509, 2018. e-Pub 2018. PMID: 29661779.
- Zhang X, Liu F, Knapp KA, Nickels ML, Manning HC, Bellan LM. A simple microfluidic platform for rapid and efficient production of the radiotracer [18F]fallypride. Lab Chip 18(9):1369-1377, 2018. PMID: 29658049.
- Tang D, Fujinaga M, Hatori A, Zhang Y, Yamasaki T, Xie L, Mori W, Kumata K, Liu J, Manning HC, Huang G, Zhang MR. Evaluation of the novel TSPO radiotracer 2-(7-butyl-2-(4-(2-([18F]fluoroethoxy)phenyl)-5-methylpyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide in a preclinical model of neuroinflammation. Eur J Med Chem 150:1-8, 2018. e-Pub 2018. PMID: 29505933.
- Schulte ML, Fu A, Zhao P, Li J, Geng L, Smith ST, Kondo J, Coffey RJ, Johnson MO, Rathmell JC, Sharick JT, Skala MC, Smith JA, Berlin J, Washington MK, Nickels ML, Manning HC. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models. Nat Med 24(2):194-202, 2018. e-Pub 2018. PMID: 29334372.
- Magarik MA, Walker RC, Gilbert J, Manning HC, Massion PP. Intracardiac Metastases Detected by 18F-FSPG PET/CT. Clin Nucl Med 43(1):28-30, 2018. PMID: 29076915.
- Zhang Q, Jeppesen DK, Higginbotham JN, Demory Beckler M, Poulin EJ, Walsh AJ, Skala MC, McKinley ET, Manning HC, Hight MR, Schulte ML, Watt KR, Ayers GD, Wolf MM, Andrejeva G, Rathmell JC, Franklin JL, Coffey RJ. Mutant KRAS Exosomes Alter the Metabolic State of Recipient Colonic Epithelial Cells. Cell Mol Gastroenterol Hepatol 5(4):627-629.e6, 2018. e-Pub 2018. PMID: 29930982.
- Luo N, Nixon MJ, Gonzalez-Ericsson PI, Sanchez V, Opalenik SR, Li H, Zahnow CA, Nickels ML, Liu F, Tantawy MN, Sanders ME, Manning HC, Balko JM. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun 9(1):248, 2018. e-Pub 2018. PMID: 29339738.
- Tantawy MN, Manning HC, Peterson TE, Colvin DC, Gore JC, Lu W, Chen Z, Chad Quarles C. Translocator Protein PET Imaging in a Preclinical Prostate Cancer Model. Mol Imaging Biol 20(2):200-204, 2018. e-Pub 2018. PMID: 28822038.
- Tang D, Li J, Buck JR, Tantawy MN, Xia Y, Harp JM, Nickels ML, Meiler J, Manning HC. Evaluation of TSPO PET Ligands [18F]VUIIS1009A and [18F]VUIIS1009B: Tracers for Cancer Imaging. Mol Imaging Biol 19(4):578-588, 2017. PMID: 27853987.
- Schulte ML, Hight MR, Ayers GD, Liu Q, Shyr Y, Washington MK, Manning HC. Non-Invasive Glutamine PET Reflects Pharmacological Inhibition of BRAFV600E In Vivo. Mol Imaging Biol 19(3):421-428, 2017. PMID: 27770401.
- Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA. 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. Clin Cancer Res 23(12):3053-3060, 2017. e-Pub 2016. PMID: 28011460.
- Xu J, Li K, Smith RA, Waterton JC, Zhao P, Ding Z, Does MD, Manning HC, Gore JC. A comparative assessment of preclinical chemotherapeutic response of tumors using quantitative non-Gaussian diffusion MRI. Magn Reson Imaging 37:195-202, 2017. e-Pub 2016. PMID: 27919785.
- Li J, Smith JA, Dawson ES, Fu A, Nickels ML, Schulte ML, Manning HC. Optimized Translocator Protein Ligand for Optical Molecular Imaging and Screening. Bioconjug Chem 28(4):1016-1023, 2017. e-Pub 2017. PMID: 28156095.
- Kavanaugh G, Williams J, Morris AS, Nickels ML, Walker R, Koglin N, Stephens AW, Washington MK, Geevarghese SK, Liu Q, Ayers D, Shyr Y, Manning HC. Utility of [18F]FSPG PET to Image Hepatocellular Carcinoma: First Clinical Evaluation in a US Population. Mol Imaging Biol 18(6):924-934, 2016. PMID: 27677886.
- Qiao J, Grabowska MM, Forestier-Roman IS, Mirosevich J, Case TC, Chung DH, Cates JM, Matusik RJ, Manning HC, Jin R. Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression. Oncotarget 7(38):61955-61969, 2016. PMID: 27542219.
- Osgood CL, Tantawy MN, Maloney N, Madaj ZB, Peck A, Boguslawski E, Jess J, Buck J, Winn ME, Manning HC, Grohar PJ. 18F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FLI1 Activity and Ewing Sarcoma. Sci Rep 6:33926, 2016. e-Pub 2016. PMID: 27671553.
- Li J, Schulte ML, Nickels ML, Manning HC. New structure-activity relationships of N-acetamide substituted pyrazolopyrimidines as pharmacological ligands of TSPO. Bioorg Med Chem Lett 26(15):3472-7, 2016. e-Pub 2016. PMID: 27353534.
- Joseph JD, Darimont B, Zhou W, Arrazate A, Young A, Ingalla E, Walter K, Blake RA, Nonomiya J, Guan Z, Kategaya L, Govek SP, Lai AG, Kahraman M, Brigham D, Sensintaffar J, Lu N, Shao G, Qian J, Grillot K, Moon M, Prudente R, Bischoff E, Lee KJ, Bonnefous C, Douglas KL, Julien JD, Nagasawa JY, Aparicio A, Kaufman J, Haley B, Giltnane JM, Wertz IE, Lackner MR, Nannini MA, Sampath D, Schwarz L, Manning HC, Tantawy MN, Arteaga CL, Heyman RA, Rix PJ, Friedman L, Smith ND, Metcalfe C, Hager JH. The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. Elife 5:e15828, 2016. e-Pub 2016. PMID: 27410477.
- Hassanein M, Hight MR, Buck JR, Tantawy MN, Nickels ML, Hoeksema MD, Harris BK, Boyd K, Massion PP, Manning HC. Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer. Mol Imaging Biol 18(1):18-23, 2016. PMID: 25971659.
- Schulte ML, Khodadadi AB, Cuthbertson ML, Smith JA, Manning HC. 2-Amino-4-bis(aryloxybenzyl)aminobutanoic acids: A novel scaffold for inhibition of ASCT2-mediated glutamine transport. Bioorg Med Chem Lett 26(3):1044-1047, 2016. e-Pub 2015. PMID: 26750251.
- Manning HC, Buck JR, Cook RS. Mouse Models of Breast Cancer: Platforms for Discovering Precision Imaging Diagnostics and Future Cancer Medicine. J Nucl Med 57 Suppl 1:60S-8S, 2016. PMID: 26834104.
- Higginbotham JN, Zhang Q, Jeppesen DK, Scott AM, Manning HC, Ochieng J, Franklin JL, Coffey RJ. Identification and characterization of EGF receptor in individual exosomes by fluorescence-activated vesicle sorting. J Extracell Vesicles 5:29254, 2016. e-Pub 2016. PMID: 27345057.
- Han W, Zaynagetdinov R, Yull FE, Polosukhin VV, Gleaves LA, Tanjore H, Young LR, Peterson TE, Manning HC, Prince LS, Blackwell TS. Molecular imaging of folate receptor β-positive macrophages during acute lung inflammation. Am J Respir Cell Mol Biol 53(1):50-9, 2015. PMID: 25375039.
- McKinley ET, Watchmaker JM, Chakravarthy AB, Meyerhardt JA, Engelman JA, Walker RC, Washington MK, Coffey RJ, Manning HC. [(18)F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study. Ann Nucl Med 29(6):535-42, 2015. e-Pub 2015. PMID: 25899481.
- Manning HC. World Molecular Imaging Congress 2015: precision medicine visualized. Mol Imaging Biol 17(3):295-6, 2015. PMID: 25862478.
- Cheung YY, Nickels ML, McKinley ET, Buck JR, Manning HC. High-yielding, automated production of 3'-deoxy-3'-[(18)F]fluorothymidine using a modified Bioscan Coincidence FDG reaction module. Appl Radiat Isot 97:47-51, 2015. e-Pub 2014. PMID: 25531913.
- Whisenant JG, McIntyre JO, Peterson TE, Kang H, Sánchez V, Manning HC, Arteaga CL, Yankeelov TE. Utility of [18?F]FLT-PET to assess treatment response in trastuzumab-resistant and trastuzumab-sensitive HER2-overexpressing human breast cancer xenografts. Mol Imaging Biol 17(1):119-28, 2015. PMID: 25034624.
- Schulte ML, Dawson ES, Saleh SA, Cuthbertson ML, Manning HC. 2-Substituted Nγ-glutamylanilides as novel probes of ASCT2 with improved potency. Bioorg Med Chem Lett 25(1):113-6, 2015. e-Pub 2014. PMID: 25435145.
- Buck JR, McKinley ET, Fu A, Abel TW, Thompson RC, Chambless L, Watchmaker JM, Harty JP, Cooper MK, Manning HC. Preclinical TSPO Ligand PET to Visualize Human Glioma Xenotransplants: A Preliminary Study. PLoS One 10(10):e0141659, 2015. e-Pub 2015. PMID: 26517124.
- Tang D, Nickels ML, Tantawy MN, Buck JR, Manning HC. Preclinical imaging evaluation of novel TSPO-PET ligand 2-(5,7-Diethyl-2-(4-(2-[(18)F]fluoroethoxy)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide ([ (18)F]VUIIS1008) in glioma. Mol Imaging Biol 16(6):813-20, 2014. PMID: 24845529.
- Comerford SA, Huang Z, Du X, Wang Y, Cai L, Witkiewicz AK, Walters H, Tantawy MN, Fu A, Manning HC, Horton JD, Hammer RE, McKnight SL, Tu BP. Acetate dependence of tumors. Cell 159(7):1591-602, 2014. PMID: 25525877.
- Cheung YY, Nickels ML, Tang D, Buck JR, Manning HC. Facile synthesis of SSR180575 and discovery of 7-chloro-N,N,5-trimethyl-4-oxo-3(6-[(18)F]fluoropyridin-2-yl)-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide, a potent pyridazinoindole ligand for PET imaging of TSPO in cancer. Bioorg Med Chem Lett 24(18):4466-4471, 2014. e-Pub 2014. PMID: 25172419.
- Powell AE, Vlacich G, Zhao ZY, McKinley ET, Washington MK, Manning HC, Coffey RJ. Inducible loss of one Apc allele in Lrig1-expressing progenitor cells results in multiple distal colonic tumors with features of familial adenomatous polyposis. Am J Physiol Gastrointest Liver Physiol 307(1):G16-23, 2014. e-Pub 2014. PMID: 24833705.
- Perrone MG, Malerba P, Uddin J, Vitale P, Panella A, Crews BC, Daniel CK, Ghebreselasie K, Nickels M, Tantawy MN, Manning HC, Marnett LJ, Scilimati A. PET radiotracer [¹8F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: preliminary investigation. Eur J Med Chem 80:562-568, 2014. e-Pub 2014. PMID: 24832612.
- Hight MR, Cheung YY, Nickels ML, Dawson ES, Zhao P, Saleh S, Buck JR, Tang D, Washington MK, Coffey RJ, Manning HC. A peptide-based positron emission tomography probe for in vivo detection of caspase activity in apoptotic cells. Clin Cancer Res 20(8):2126-35, 2014. e-Pub 2014. PMID: 24573549.
- Uddin MI, Buck JR, Schulte ML, Tang D, Saleh SA, Cheung YY, Harp J, Manning HC. Microwave-assisted, one-pot reaction of 7-azaindoles and aldehydes: a facile route to novel di-7-azaindolylmethanes. Tetrahedron Lett 55(1), 2014. PMID: 24396154.
- McKinley ET, Zhao P, Coffey RJ, Washington MK, Manning HC. 3'-Deoxy-3'-[18F]-Fluorothymidine PET imaging reflects PI3K-mTOR-mediated pro-survival response to targeted therapy in colorectal cancer. PLoS One 9(9):e108193, 2014. e-Pub 2014. PMID: 25247710.
- Katsha A, Soutto M, Sehdev V, Peng D, Washington MK, Piazuelo MB, Tantawy MN, Manning HC, Lu P, Shyr Y, Ecsedy J, Belkhiri A, El-Rifai W. Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia. Gastroenterology 145(6):1312-22.e1-8, 2013. e-Pub 2013. PMID: 23993973.
- Goode GD, Ballard BR, Manning HC, Freeman ML, Kang Y, Eltom SE. Knockdown of aberrantly upregulated aryl hydrocarbon receptor reduces tumor growth and metastasis of MDA-MB-231 human breast cancer cell line. Int J Cancer 133(12):2769-80, 2013. e-Pub 2013. PMID: 23733406.
- Walsh AJ, Cook RS, Manning HC, Hicks DJ, Lafontant A, Arteaga CL, Skala MC. Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer. Cancer Res 73(20):6164-74, 2013. PMID: 24130112.
- Xie J, Wang C, Virostko J, Manning HC, Pham W, Bauer J, Gore JC. A novel reporter system for molecular imaging and high-throughput screening of anticancer drugs. Chembiochem 14(12):1494-503, 2013. e-Pub 2013. PMID: 23881799.
- Tang D, McKinley ET, Hight MR, Uddin MI, Harp JM, Fu A, Nickels ML, Buck JR, Manning HC. Synthesis and structure-activity relationships of 5,6,7-substituted pyrazolopyrimidines: discovery of a novel TSPO PET ligand for cancer imaging. J Med Chem 56(8):3429-33, 2013. e-Pub 2013. PMID: 23521048.
- McKinley ET, Smith RA, Zhao P, Fu A, Saleh SA, Uddin MI, Washington MK, Coffey RJ, Manning HC. 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer. J Nucl Med 54(3):424-30, 2013. e-Pub 2013. PMID: 23341544.
- McKinley ET, Ayers GD, Smith RA, Saleh SA, Zhao P, Washington MK, Coffey RJ, Manning HC. Limits of [18F]-FLT PET as a biomarker of proliferation in oncology. PLoS One 8(3):e58938, 2013. e-Pub 2013. PMID: 23554961.
- Thompson MM, Manning HC, Ellacott KL. Translocator protein 18 kDa (TSPO) is regulated in white and brown adipose tissue by obesity. PLoS One 8(11):e79980, 2013. e-Pub 2013. PMID: 24260329.
- McKinley ET, Liu H, McDonald WH, Luo W, Zhao P, Coffey RJ, Hanks SK, Manning HC. Global phosphotyrosine proteomics identifies PKCδ as a marker of responsiveness to Src inhibition in colorectal cancer. PLoS One 8(11):e80207, 2013. e-Pub 2013. PMID: 24260357.
- Walsh AJ, Cook RS, Manning HC, Hicks DJ, Lafontant A, Arteaga CL, Skala MC. Autofluorescence Imaging Resolves Early Cancer Treatment Response In Vivo. Technical Digest (online)(Optical Society of America), 2013.
- Yankeelov TE, Peterson TE, Abramson RG, Izquierdo-Garcia D, Arlinghaus LR, Li X, Atuegwu NC, Catana C, Manning HC, Fayad ZA, Gore JC. Simultaneous PET-MRI in oncology: a solution looking for a problem?. Magn Reson Imaging 30(9):1342-56, 2012. e-Pub 2012. PMID: 22795930.
- McKinley ET, Smith RA, Tanksley JP, Washington MK, Walker R, Coffey RJ, Manning HC. [18F]FLT-PET to predict pharmacodynamic and clinical response to cetuximab therapy in Ménétrier's disease. Ann Nucl Med 26(9):757-63, 2012. e-Pub 2012. PMID: 22821337.
- Wang C, Xie J, Guo J, Manning HC, Gore JC, Guo N. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer. Oncol Rep 28(4):1301-8, 2012. e-Pub 2012. PMID: 22895640.
- Buck JR, Saleh S, Uddin MI, Manning HC. Rapid, Microwave-Assisted Organic Synthesis of Selective (V600E)BRAF Inhibitors for Preclinical Cancer Research. Tetrahedron Lett 53(32):4161-4165, 2012. e-Pub 2012. PMID: 23180892.
- Wyatt SK, Manning HC, Bai M, Ehtesham M, Mapara KY, Thompson RC, Bornhop DJ. Preclinical molecular imaging of the translocator protein (TSPO) in a metastases model based on breast cancer xenografts propagated in the murine brain. Curr Mol Med 12(4):458-66, 2012. PMID: 22348613.
- Myers MV, Manning HC, Coffey RJ, Liebler DC. Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling. Mol Cell Proteomics 11(2):M111.015222, 2012. e-Pub 2011. PMID: 22147731.
- Tang D, Hight MR, McKinley ET, Fu A, Buck JR, Smith RA, Tantawy MN, Peterson TE, Colvin DC, Ansari MS, Nickels M, Manning HC. Quantitative preclinical imaging of TSPO expression in glioma using N,N-diethyl-2-(2-(4-(2-18F-fluoroethoxy)phenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide. J Nucl Med 53(2):287-94, 2012. e-Pub 2012. PMID: 22251555.
- Xu J, Li K, Smith RA, Waterton JC, Zhao P, Chen H, Does MD, Manning HC, Gore JC. Characterizing tumor response to chemotherapy at various length scales using temporal diffusion spectroscopy. PLoS One 7(7):e41714, 2012. e-Pub 2012. PMID: 22911846.
- Fox EM, Miller TW, Balko JM, Kuba MG, Sánchez V, Smith RA, Liu S, González-Angulo AM, Mills GB, Ye F, Shyr Y, Manning HC, Buck E, Arteaga CL. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res 71(21):6773-84, 2011. e-Pub 2011. PMID: 21908557.
- Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Maira SM, Manning HC, González-Angulo AM, Mills GB, Higham C, Chanthaphaychith S, Kuba MG, Miller WR, Shyr Y, Arteaga CL. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 1(4):338-51, 2011. e-Pub 2011. PMID: 22049316.
- Gore JC, Manning HC, Quarles CC, Waddell KW, Yankeelov TE. Magnetic resonance in the era of molecular imaging of cancer. Magn Reson Imaging 29(5):587-600, 2011. e-Pub 2011. PMID: 21524870.
- McKinley ET, Bugaj JE, Zhao P, Guleryuz S, Mantis C, Gokhale PC, Wild R, Manning HC. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Clin Cancer Res 17(10):3332-40, 2011. e-Pub 2011. PMID: 21257723.
- Guo N, Xie J, Manning HC, Deane NG, Ansari MS, Coffey RJ, Gore J, Price RR, Baldwin RM, McIntyre JO. A novel in vitro assay to assess phosphorylation of 3'-[(18)F]fluoro-3'-deoxythymidine. Mol Imaging Biol 13(2):257-64, 2011. PMID: 20532643.
- Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, Manning HC, Chang J, Arteaga CL. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A 108(12):5021-6, 2011. e-Pub 2011. PMID: 21385943.
- Buck JR, McKinley ET, Hight MR, Fu A, Tang D, Smith RA, Tantawy MN, Peterson TE, Colvin D, Ansari MS, Baldwin RM, Zhao P, Guleryuz S, Manning HC. Quantitative, preclinical PET of translocator protein expression in glioma using 18F-N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline. J Nucl Med 52(1):107-14, 2011. e-Pub 2010. PMID: 21149488.
- Smith RA, Guleryuz S, Manning HC. Molecular imaging metrics to evaluate response to preclinical therapeutic regimens. Front Biosci (Landmark Ed) 16(2):393-410, 2011. e-Pub 2011. PMID: 21196177.
- Hight MR, Nolting DD, McKinley ET, Lander AD, Wyatt SK, Gonyea M, Zhao P, Manning HC. Multispectral fluorescence imaging to assess pH in biological specimens. J Biomed Opt 16(1):016007, 2011. PMID: 21280913.
- Tang D, Buck JR, Hight MR, Manning HC. Microwave-assisted Organic Synthesis of a High-affinity Pyrazolo-pyrimidinyl TSPO Ligand. Tetrahedron Lett 51(35):4595-4598, 2010. PMID: 20689673.
- Wyatt SK, Manning HC, Bai M, Bailey SN, Gallant P, Ma G, McIntosh L, Bornhop DJ. Molecular imaging of the translocator protein (TSPO) in a pre-clinical model of breast cancer. Mol Imaging Biol 12(3):349-58, 2010. e-Pub 2009. PMID: 19949989.
- Ayers GD, McKinley ET, Zhao P, Fritz JM, Metry RE, Deal BC, Adlerz KM, Coffey RJ, Manning HC. Volume of preclinical xenograft tumors is more accurately assessed by ultrasound imaging than manual caliper measurements. J Ultrasound Med 29(6):891-901, 2010. PMID: 20498463.
- Miller TW, Forbes JT, Shah C, Wyatt SK, Manning HC, Olivares MG, Sanchez V, Dugger TC, de Matos Granja N, Narasanna A, Cook RS, Kennedy JP, Lindsley CW, Arteaga CL. Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res 15(23):7266-76, 2009. e-Pub 2009. PMID: 19934303.
- Sexton M, Woodruff G, Cudaback E, Kreitzer FR, Xu C, Lin YH, Möller T, Bai M, Manning HC, Bornhop D, Stella N. Binding of NIR-conPK and NIR-6T to astrocytomas and microglial cells: evidence for a protein related to TSPO. PLoS One 4(12):e8271, 2009. e-Pub 2009. PMID: 20020060.
- Yankeelov TE, Avison MJ, Damon BM, Manning HC, Peterson TE, Gore JC. Frontiers of Biomedical Imaging Science 2009: workshop report and research opportunities. Cancer Res 69(20):7902-4, 2009. e-Pub 2009. PMID: 19808955.
- Peterson TE, Manning HC. Molecular imaging: 18F-FDG PET and a whole lot more. J Nucl Med Technol 37(3):151-61, 2009. e-Pub 2009. PMID: 19692452.
- Shah C, Miller TW, Wyatt SK, McKinley ET, Olivares MG, Sanchez V, Nolting DD, Buck JR, Zhao P, Ansari MS, Baldwin RM, Gore JC, Schiff R, Arteaga CL, Manning HC. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res 15(14):4712-21, 2009. e-Pub 2009. PMID: 19584166.
- Virostko J, Xie J, Hallahan DE, Arteaga CL, Gore JC, Manning HC. A molecular imaging paradigm to rapidly profile response to angiogenesis-directed therapy in small animals. Mol Imaging Biol 11(3):204-12, 2009. e-Pub 2009. PMID: 19130143.
- Manning HC, Shay SD, Mericle RA. Multispectral molecular imaging of capillary endothelium to facilitate preoperative endovascular brain mapping. J Neurosurg 110(5):975-80, 2009. PMID: 19231927.
- Manning HC, Merchant NB, Foutch AC, Virostko JM, Wyatt SK, Shah C, McKinley ET, Xie J, Mutic NJ, Washington MK, LaFleur B, Tantawy MN, Peterson TE, Ansari MS, Baldwin RM, Rothenberg ML, Bornhop DJ, Gore JC, Coffey RJ. Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. Clin Cancer Res 14(22):7413-22, 2008. PMID: 19010858.
- Manning HC, Lander A, McKinley E, Mutic NJ. Accelerating the development of novel molecular imaging probes: a role for high-throughput screening. J Nucl Med 49(9):1401-4, 2008. e-Pub 2008. PMID: 18703594.
- Manning HC. Optical imaging shines in vivo. Journal of Nuclear Medicine 49(1):23N-+, 2008.
- Deane NG, Manning HC, Foutch AC, Washington MK, Aronow BJ, Aronow BA, Bornhop DJ, Coffey RJ. Targeted imaging of colonic tumors in smad3-/- mice discriminates cancer and inflammation. Mol Cancer Res 5(4):341-9, 2007. PMID: 17426249.
- Manning HC, Shay SD, Santra S, Richter EO, Mericle RA. Endovascular Brain Mapping: An Intraoperative Strategy for Visualizing Functional Brain Parenchyma. Brain Research 1(4):217-34, 2007.
- Manning HC, Smith SM, Sexton M, Haviland S, Bai M, Cederquist K, Stella N, Bornhop DJ. A peripheral benzodiazepine receptor targeted agent for in vitro imaging and screening. Bioconjug Chem 17(3):735-40, 2006. PMID: 16704212.
- Smentek L, Hess BA, Cross JP, Manning HC, Bornhop DJ. Density-functional theory structures of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid complexes for ions across the lanthanide series. J Chem Phys 123(24), 2005. PMID: 16396532.
- Manning HC, Bai MF, Anderson BM, Lisiak R, Samuelson LE, Bornhop DJ. Expeditious synthesis of 'P'-protected macrocycles en route to lanthanide chelate metal complexes. Tetrahedron letters 46(28):4707-10, 2005.
- Manning HC, Goebel T, Thompson RC, Price RR, Lee H, Bornhop DJ. Targeted molecular imaging agents for cellular-scale bimodal imaging. Bioconjug Chem 15(6):1488-95, 2004. PMID: 15546219.
- Manning HC, Skwierawska A, Marx JN, Bornhop DJ. Rapid removal of benzyloxycarbonyl groups from 1,4,7,10-tetraazacyclododecane derivatives by catalytic transfer hydrogenation. Synthetic Commun 33(3):457-61, 2003.
- Manning HC, Goebel T, Marx JN, Bornhop DJ. Facile, efficient conjugation of a trifunctional lanthanide chelate to a peripheral benzodiazepine receptor ligand. Org Lett 4(7):1075-8, 2002. PMID: 11922786.
- Griffin JMM, Skwierawska AM, Manning HC, Marx JN, Bornhop DJ. Simple, high yielding synthesis of trifunctional fluorescent lanthanide chelates. Tetrahedron letters 42(23):3823-5, 2001. PMID: ISI:000168959100014.
- Gammon ST, Cohen AS, Lehnert AL, Sullivan D, Malyarenko D, Manning HC, Hormuth D, Daldrup-Link H, An H, Quirk JD, Shoghi K, Pagel MD, Kinahan PE, Miyaoka RS, Lewis MT, Larson P, Sriram R, Blocker SJ, Pickup S, Badea A, Badea CT, Chenevert TL. An Online Repository for Pre-clinical Imaging Protocols (PIPs). Tomography.
Invited Articles
- Manning HC. Thymidine kinase 1 (TK1) regulation in oncology: impact on [18F]FLT PET as a cancer imaging biomarker. Society of Nuclear Medicine (SNM) Molecular Imaging Gateway 4(2):1-3, 2010.
- Manning HC. Accelerating the development of novel molecular imaging probes: A role for high-throughput screening. Society of Nuclear Medicine (SNM) Molecular Imaging Gateway 2(1):1-4, 2008.
- Manning HC. Molecular imaging: Images of Interest. Society of Nuclear Medicine (SNM) Molecular Imaging Gateway 1(1):5, 2007.
- Manning HC, Foutch AC, Deane NG, Merchant N, Wyatt SK, Bai M, Bornhop DJ, Coffey RJ. A High-Throughput Molecular Imaging Screen to Monitor Therapeutic Response In Vivo. Cambridge Health Institute: Third annual “In Vivo Molecular Imaging, 2006.
Editorials
- Manning HC. Passing the Molecular Imaging and Biology Torch. Mol Imaging Biol 26(2):189-190, 2024. PMID: 38512546.
Abstracts
- Malyarenko D, Amouzandeh G, Pickup S, Zhou R, Manning HC, Gammon ST, Shoghi KI, Quirk JD, Sriram R, Larson P, Lewis MT, Pautler RG, Kinahan PE, Muzi M, Chenevert TL. ADC Repeatability and Reproducibility of NCI CIRP Network Pre-Clinical MRIs. ISMRM Annual Meeting June 03-08, 2023, 2022.
- Bae SW, Manning HC. Preclinical Evaluation of 4-[18F]Fluoroglutamine PET predicts response to combined Inhibition of EGFR and glutaminolysis in KRAS wild-type metastatic colorectal cancer. WMIC 2022 - World Molecular Imaging Congress, 2022.
- Coll R, Manning HC. Overexpressed transmembrane glycoprotein MUC13 is targeted by a zirconium-89 radiolabeled antibody as viewed by PET imaging in a colorectal cancer xenograft mouse model. WMIC 2022 - World Molecular Imaging Congress, 2022.
- Bae SW, Manning HC. Feasibility of PET imaging for predicting response to combined Inhibition of EGFR and glutaminolysis in KRAS WT CRC. 2022 CSI Spring Retreat, 2022.
- Wen XX, Manning HC. Detection of HCC Tumors by 18F-FSPG PET in High-Fat-Diet Fed MUP-µPA Transgenic Mouse Model. 2022 CSI Spring Retreat, 2022.
- Pham CD, Manning HC. Synthesis Methodology Towards Novel ASCT2 Inhibitors. 2022 CSI Spring Retreat, 2022.
- Coll R, Manning HC. A Study in Targeting Epithelial Carcinomas Using a 89Zr-Radiolabeled Anti-MUC13 Antibody. 2022 CSI Spring Retreat, 2022.
- Wang JB, Manning HC. Screening the Potential Best Candidate of Small Molecule Inhibitors of Cancer Metabolism. 2022 CSI Spring Retreat, 2022.
- Paez R, Shah C, Connelly CC, Myczkowski C, Muterspaugh A, Helton T, Manning HC, Smith G, Walker RC, Massion PP. 18F-FSPG PET imaging for the evaluation of indeterminate pulmonary nodules. American Thoracic Society Conference, 2020.
- Marcu L, Vernier PT, Manning HC, Salemi S, Li A, Craft CM, Gundersen MA, Bornhop D. Fluorescence microscopy studies of a peripheral-benzodiazepine-receptor-targeted molecular probe for brain tumor imaging. Proceedings of SPIE-The International Society for Optical Engineering:64-9. e-Pub 2003.
- Manning HC, Goebel T, Bornhop DJ. Synthesis and Physical Spectroscopy of Lanthanide Chelates as Contrast Agents. Photonics West (The International Society for Optical Engineering: SPIE), 2002.
- Manning HC, Goebel TS, Weigel M, Bornhop DJ. Lanthanide Chelates as Multi-Use Molecular Imaging Agents. The International Society for Optical Engineering (SPIE), 2002.
Book Chapters
- Buck JR, Hight MR, Tang D, Manning HC. Contrast agents for T1-weighted MRI. In: Quantitative MRI in Cancer. CRC Press, Imaging in Medical Diagnosis and Therapy Series, 2011.
- Gore JC, Manning HC, Peterson TE, Quarles CC, Sinha TK, Yankeelov T. Quantitative Imaging Biomarkers of Cancer. In: Advances in Medical Physics. Medical Physics Publishing: Madison Wisconsin, 2010.
- Manning HC, Wyatt SK, Goebel TS, Griffin JM, Kiefer G, Motamedi M, Bell B, Thompson RC, Ehtesham M, Cederquist K, Bornhop DJ. Lanthanide Complexes as Optical Imaging Agents. In: Recent Advances of Bioconjugate Chemistry in Molecular Imaging. Research Signpost, 283-307, 2008.
- Gore JC, Joers JM, Manning HC, Kennan RP. Contrast Agents and Relaxation Effects. In: MRI of the Brain and Spine. 4th. Lippincott Williams & Wilkins, 2008.
Grant & Contract Support
| Title: | VUMC Cancer Center Support Grant |
| Funding Source: | NIH/NCI |
| Role: | Director of Cancer Imaging Research; Director of Animal and Human Imaging Shared Resource |
| Title: | Molecular and Cellular Basis for Digestive Diseases |
| Funding Source: | NIH/NIDDK |
| Role: | Preclinical Models of Digestive Disease Core Co-Director (Imaging) |
| Title: | NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade |
| Funding Source: | NIH/NIDDK |
| Role: | Co-Investigator |
| Title: | Hormonal, Metabolic and Signaling Interactions in PAH |
| Funding Source: | NIH/NHLBI |
| Role: | Co-Investigator |
| Title: | MDACC PREDICT |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | VUMC - Development and evaluation of new ASCT2 inhibitors |
| Funding Source: | Dracen Pharmaceuticals |
| Role: | Principal Investigator |
| Title: | Therapeutic Targeting of the Glutamine Transporter SLC1A5 in Advanced Prostate Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-Investigator |
| Title: | Vanderbilt-Ingram Cancer Center SPORE in Gastrointestinal Cancer |
| Funding Source: | Vanderbilt University Medical Center / NIH / NCI |
| Role: | Principal Investigator-MDACC |
| Title: | Pharmacological Inhibitors of Cancer Metabolism |
| Funding Source: | Dracen Pharmaceuticals |
| Role: | Principal Investigator |
| Title: | Quantitative PET Imaging of Hepatocellular Carcinoma (HCC) |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | General Electric Immuno-Oncology Center of Excellence |
| Funding Source: | General Electric |
| Role: | Principal Investigator |
| Title: | VUMC - SPORE in Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | VUMC - Evaluation of Glutamine Metabolism Inhibitors; Study Phase 1 |
| Funding Source: | Dracen Pharmaceuticals |
| Role: | Principal Investigator |
| Title: | VUMC - TSPO Ligands for Cancer Imaging |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | VUMC - Role of EGFR Ligand-containing Exosomes in Colorectal Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | VUMC - MRI Diffusion in Tumors Using Oscillating Gradients |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | VUMC - Multidisciplinary Training in Basic and Translational Imaging of Cancer |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | VUMC - Roles for Lrig1 in Intestinal Neoplasia |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | VUMC - A Simple and Effective Diagnostic Test for Gastrointestinal Bleeding to Improve Patient Outcomes |
| Funding Source: | NIH/NIDDK |
| Role: | Principal Investigator |
| Title: | VUMC - Comprehensive Evaluation of OGSE DWI for Assessing Tumor Treatment Response |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | VUMC - Multimodal Immunoimaging for Screening Lung Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Principal Investigator |
| Title: | VUMC - SPORE in Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | VUMC - Targeting the Epithelial Type II Interleukin-4 Receptor in Metastatic Breast Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-Investigator |
| Title: | VUMC - Imaging Activated Macrophages in the Lungs |
| Funding Source: | NIH/NHLBI |
| Role: | Co-Principal Investigator |
| Title: | Effect of tumor cell glutamine metabolism on anti-tumor immunity in TNBC |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | CPRIT Recruitment - Established Investigator |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Principal Investigator |
| Title: | STARs Award |
| Funding Source: | The University of Texas System Science & Technology Acquisition and Retention (STARs) Award |
| Role: | Principal Investigator |
| Title: | Glutamine PET Imaging of Head and Neck Cancers |
| Funding Source: | The University of Texas MD Anderson Cancer Center - Institutional Research Grant |
| Role: | Principal Investigator |
| Title: | Novel PET Imaging to Guide Yttrium-90 Radioembolization Therapy in Hepatocellular Carcinoma |
| Funding Source: | MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma |
| Role: | Principal Investigator |
| Title: | Disrupting Access to Intracellular Lipid Depots to Treat Advanced Prostate Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-Investigator |
| Title: | [18F]4FN PET Imaging of Innate Immunity Activation During Immunotherapy-Induced Adverse Events |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | Annotating Metabolic Vulnerabilities in Cholangiocarcinoma with Non-invasive PET Imaging |
| Funding Source: | The University of Texas MD Anderson Cancer Center/CCSG ROCIP Award |
| Role: | Principal Investigator |
| Title: | Glutamine Metabolism-targeted Therapeutics for Melanoma |
| Funding Source: | The University of Texas MD Anderson Cancer Center/NIH |
| Role: | Principal Investigator |
| Title: | Interdisciplinary Translational Pre/Postdoctoral Program in Cancer Nanotechnology |
| Funding Source: | NIH/NCI |
| Role: | Mentor |
Patient Reviews
CV information above last modified December 06, 2024